Butterfly Network Strengthens Executive Team with Two C-Suite Appointments

By: Butterfly Network, Inc. via Business Wire

May 12, 2022 at 16:05 PM EDT

Company Announces Hiring of Tamara Dillon as Chief People Officer and Larry Weiss as Chief Legal Officer and Corporate Secretary

Both Executives Bring Healthcare, Public Company, and Growth Experience to their Respective Roles

Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound, today announced the appointment of Tamara Dillon to the position of Chief People Officer (CPO), effective May 31, and Larry Weiss to the position of Chief Legal Officer and Corporate Secretary, effective May 23.

“The addition of Tamara and Larry brings two extraordinary leaders with great depth of experience working within public companies, scaling talent, and respectively building and leading teams and functions to support growth,” said Dr. Todd Fruchterman, Butterfly Network's President and Chief Executive Officer. “As we continue to execute on our strategy, expand the value we bring to global healthcare, and deliver upon our commitment to make Butterfly one of the most valuable and essential clinical assessment tools for medical professionals and the patients in their care, the roles of Chief People Officer and Chief Legal Officer are foundational to our organization. I look forward to working with and alongside Tamara and Larry in their new roles with Butterfly.”

Tamara joins Butterfly from Akebia Therapeutics where she served as Senior Vice President of Human Resources and Chief People Officer. During her almost eight years at Akebia she played an integral role in scaling the company and was instrumental in developing talent and culture. She also led the company’s Diversity Equity and Inclusion and Patient Advocacy functions. Before Akebia, Tamara served as Head of Human Resources, Global Discovery Chemistry at Novartis Institutes for BioMedical Research, where she was responsible for all aspects of human resources. She also held several key roles at Genzyme, a Sanofi Company.

Larry brings nearly 30 years of experience as an attorney, including 20 years in the medical device industry with Medtronic, Covidien, and Tyco Healthcare. Most recently, he served as Chief Legal Officer for Emulate, a venture capital backed life sciences start-up and as General Counsel and Corporate Secretary of Analog Devices, a publicly traded semiconductor company.

On her new role at Butterfly, Tamara commented, “I look forward to joining the Butterfly team and supporting its commitment to democratize healthcare through innovation and enabling more informed healthcare decisions. The people organization is the heartbeat to any healthy company, especially one with the important goal of benefiting patients around the world. I’m excited and proud to step into this role and be part of the Butterfly team.”

On his new role at Butterfly, Larry commented, “I am excited to be a part of the next chapter of growth and evolution at Butterfly. I’m extremely motivated by Butterfly’s mission to make medical imaging available to everyone in the world, enabling more informed care decisions at the bedside. Butterfly is pursuing a goal that is both important and transformative; I am honored to come aboard and be part of the talented Butterfly team.”

To learn more about Butterfly Network please go to: https://www.butterflynetwork.com/.

About Butterfly Network

Founded by Dr. Jonathan Rothberg in 2011 and listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly created the world's first handheld, single probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ can be purchased online today by healthcare practitioners in the United States, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, New Zealand, Norway, Poland, Portugal, Sweden, Switzerland, and the United Kingdom.

Butterfly iQ+ is a prescription device intended for trained healthcare professionals only.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to financial results, future performance, development of products and services, and the size and potential growth of current or future markets for its products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company’s business, including issues relating to Omicron or other variants; the ability to recognize the anticipated benefits of the business combination; the Company’s ability to grow and manage growth profitably; the success, cost and timing of the Company’s product and service development activities; the potential attributes and benefits of the Company’s products and services; the degree to which our products and services are accepted by healthcare practitioners and patients for their approved uses; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing license, manufacture, supply and distribution agreements; manufacturing and supply of the Company’s products; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; changes in applicable laws or regulations; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using its products and services; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s ability to raise financing in the future; and other risks and uncertainties indicated from time to time in the Company’s most recent Annual Report on Form 10-K or in subsequent filings that it makes with the Securities and Exchange Commission. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions you not to place undue reliance upon any forward-looking statements, which speak only as of the date of this press release. The Company does not undertake or accept any obligation or undertake to release publicly any updates or revisions to any forward-looking statements to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based.